China’s Pharma industrial transformation
The Sixth Session of “China and the World” Pharmaceutical Summit, co-organized by UBM EMEA and the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) kicked off in Shanghai International Convention Center on June 23.
Nowadays, China’s economy has entered a slow-growing pattern of “New Normal,” under which the pharmaceutical industry faced new challenges and choices. This summit, with the theme of “the Wisdom and Action of China’s Pharmaceutical Industrial Transformation under the New Normal” is a good opportunity for the industrial leaders at home and abroad to discuss the future plan.
Liu Zhanglin, the vice president of CCCMHPIE, pointed out in the speech that the domestic pharmaceutical industry has gained lots of valuable experiences and strengthened the say in the international pharmaceutical market by taking active part in the international labor division.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze